MIMS travel tables updated with new rabies and hepatitis B recommendations

The National Travel Health Network and Centre (NaTHNaC) has revised the list of countries for which vaccination against rabies and hepatitis B should be considered before travel.

Exposure to bats or their secretions should be considered as a potential rabies risk for all countries and local advice should be sought regarding post-exposure treatment. | SCIENCE PHOTO LIBRARY
Exposure to bats or their secretions should be considered as a potential rabies risk for all countries and local advice should be sought regarding post-exposure treatment. | SCIENCE PHOTO LIBRARY

Rabies

Clinicians should consider pre-exposure rabies vaccination for adults and children travelling to risk countries, particularly those visiting remote areas with limited access to medical care and where the rabies vaccine and immunoglobulin may not be readily available. 

NaTHNaC now indicates where the risk of rabies transmission is thought to be restricted to contact with the saliva of an infected bat (via bites, scratches or saliva contact with mucous membranes). Travellers visiting such countries should be advised to avoid contact with bats and vaccination should be considered for those at increased risk (eg, certain occupations, such as veterinary work).

Hepatitis B 

Hepatitis B vaccination should be considered for all adults and children but is recommended for those travelling to countries where 2% or more of the population is persistently infected with the hepatitis B virus. Travellers at increased risk include those who:

  • may have unprotected sex
  • may be directly exposed to blood or blood products through their occupation (eg, healthcare professionals)
  • are participating in contact sports
  • may be exposed to contaminated needles through drug use or accessing medical or dental care
  • intend to undergo renal dialysis whilst overseas
  • are adopting children from the country 
  • are long-stay travellers

Available online and in print

The changes are reflected in the MIMS September print edition and country pages online.

Follow MIMS on Twitter

Sign up for MIMS bulletins


Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more